The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers
The response of triple-negative breast cancer (TNBC) patients to pre-operative (neoadjuvant chemotherapy) is a critical factor of their outcome. To determine the effects of chemotherapy on the tumor genome and to identify mutations associated with chemoresistance and sensitivity, we performed whole exome sequencing on pre/post-chemotherapy tumors and matched lymphocytes from 26 patients. We observed great inter-tumoral heterogeneity with no gene mutated recurrently in more than four tumors besides TP53. Although the degree of response to chemotherapy in residual tumors was associated with more subclonal changes during chemotherapy, there was minimal evolution between pre/post-tumors. Indeed, gene sets enriched for mutations in pre- and post-chemotherapy tumors were very similar and reflected genes involved in the biological process of neurogenesis. Somatically mutated genes present in chemosensitive tumors included COL1A2, PRMD15, APOBEC3B, PALB2 and histone protein encoding genes, while BRCA1, ATR, ARID1A, XRCC3 and genes encoding for tubulin-associated proteins were present in the chemoresistant tumors. We also found that the mutational spectrum of post-chemotherapy tumors was more reflective of matching metastatic tumor biopsies than pre-chemotherapy samples. These findings support a portrait of modest ongoing genomic instability with respect to single-nucleotide variants induced by or selected for by chemotherapy in TNBCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Genes - 15(2023), 1 vom: 23. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aguilar-Mahecha, Adriana [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 28.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/genes15010027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367454017 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367454017 | ||
| 003 | DE-627 | ||
| 005 | 20240128232016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/genes15010027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM367454017 | ||
| 035 | |a (NLM)38254917 | ||
| 035 | |a (PII)27 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aguilar-Mahecha, Adriana |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 28.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The response of triple-negative breast cancer (TNBC) patients to pre-operative (neoadjuvant chemotherapy) is a critical factor of their outcome. To determine the effects of chemotherapy on the tumor genome and to identify mutations associated with chemoresistance and sensitivity, we performed whole exome sequencing on pre/post-chemotherapy tumors and matched lymphocytes from 26 patients. We observed great inter-tumoral heterogeneity with no gene mutated recurrently in more than four tumors besides TP53. Although the degree of response to chemotherapy in residual tumors was associated with more subclonal changes during chemotherapy, there was minimal evolution between pre/post-tumors. Indeed, gene sets enriched for mutations in pre- and post-chemotherapy tumors were very similar and reflected genes involved in the biological process of neurogenesis. Somatically mutated genes present in chemosensitive tumors included COL1A2, PRMD15, APOBEC3B, PALB2 and histone protein encoding genes, while BRCA1, ATR, ARID1A, XRCC3 and genes encoding for tubulin-associated proteins were present in the chemoresistant tumors. We also found that the mutational spectrum of post-chemotherapy tumors was more reflective of matching metastatic tumor biopsies than pre-chemotherapy samples. These findings support a portrait of modest ongoing genomic instability with respect to single-nucleotide variants induced by or selected for by chemotherapy in TNBCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chemoresistance | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a exome sequencing | |
| 650 | 4 | |a genomics | |
| 650 | 4 | |a mutations | |
| 650 | 4 | |a triple-negative breast cancer | |
| 650 | 7 | |a Histones |2 NLM | |
| 650 | 7 | |a APOBEC3B protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.4.5 |2 NLM | |
| 650 | 7 | |a Cytidine Deaminase |2 NLM | |
| 650 | 7 | |a EC 3.5.4.5 |2 NLM | |
| 650 | 7 | |a Minor Histocompatibility Antigens |2 NLM | |
| 700 | 1 | |a Alirezaie, Najmeh |e verfasserin |4 aut | |
| 700 | 1 | |a Lafleur, Josiane |e verfasserin |4 aut | |
| 700 | 1 | |a Bareke, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Przybytkowski, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallone, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Salem, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Pelmus, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Aleynikova, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Greenwood, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Lovato, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrario, Cristiano |e verfasserin |4 aut | |
| 700 | 1 | |a Boileau, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Mihalcioiu, Catalin |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Josée-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Discepola, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Majewski, Jacek |e verfasserin |4 aut | |
| 700 | 1 | |a Basik, Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genes |d 2011 |g 15(2023), 1 vom: 23. Dez. |w (DE-627)NLM220446326 |x 2073-4425 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:23 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/genes15010027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 23 |c 12 | ||